|
1
|
Kristensen MH, Pedersen PL, Melsen GV, et
al: Variants in the dihydropyrimidine dehydrogenase,
methylenetetrahydrofolate reductase and thymidylate synthase genes
predict early toxicity of 5-fluorouracil in colorectal cancer
patients. J Int Med Res. 38:870–883. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
van Kuilenburg ABP, Meinsma R, Zonnenberg
BA, Zoetekouw L, Baas F, Matsuda K, Tamaki N and van Gennip AH:
Dihydropyrimidinase deficiency and severe 5-fluorouracil toxicity.
Clin Cancer Res. 9:4363–4367. 2003.PubMed/NCBI
|
|
3
|
Grem JL: 5-Fluorouracil: Forty-plus and
still ticking. A review of its preclinical and clinical
development. Invest New Drugs. 18:299–313. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Twelves C, Wong A, Nowacki MP, Abt M,
Burris H III, Carrato A, Cassidy J, Cervantes A, Fagerberg J,
Georgoulias V, et al: Capecitabine as adjuvant treatment for stage
III colon cancer. N Engl J Med. 352:2696–2704. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Boisdron Celle, Remaud G, Traore S,
Poirier AL, Gamelin L, Morel A and Gamelin E:
5-Fluorouracil-related severe toxicity: A comparison of different
methods for the pretherapeutic detection of dihydropyrimidine
dehydrogenase deficiency. Cancer Lett. 249:271–282. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Saif MW, Choma A, Salamone SJ and Chu E:
Pharmacokinetically guided dose adjustment of 5-fluorouracil: A
rational approach to improving therapeutic outcomes. J Natl Cancer
Inst. 101:1543–1552. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Van Kuilenburg AB, Vreken P, Beex LV,
Meinsma R, Van Lenthe H, De Abreu RA and van Gennip AH:
Heterozygosity for a point mutation in an invariant splice donor
site of dihydropyrimidine dehydrogenase and severe 5-fluorouracil
related toxicity. Eur J Cancer. 33:2258–2264. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ezzeldin H and Diasio R: Dihydropyrimidine
dehydrogenase deficiency, a pharmacogenetic syndrome associated
with potentially life-threatening toxicity following 5-fluorouracil
administration. Clin Colorectal Cancer. 4:181–189. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Schwab M, Zanger UM, Marx C, et al: German
5-FU Toxicity Study Group: Role of genetic and nongenetic factors
for fluorouracil treatment-related severe toxicity: A prospective
clinical trial by the German 5-FU Toxicity Study Group. J Clin
Oncol. 26:2131–2138. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Afzal S, Gusella M, Vainer B, et al:
Combinations of polymorphisms in genes involved in the
5-Fluorouracil metabolism pathway are associated with
gastrointestinal toxicity in chemotherapy-treated colorectal cancer
patients. Clin Cancer Res. 17:3822–3829. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Lecomte T, Ferraz JM, Zinzindohoué F,
Loriot MA, Tregouet DA, Landi B, Berger A, Cugnenc PH, Jian R,
Beaune P, et al: Thymidylate synthase gene polymorphism predicts
toxicity in colorectal cancer patients receiving
5-fluorouracil-based chemotherapy. Clin Cancer Res. 10:5880–5888.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Chazal M, Etienne MC, Renée N, Bourgeon A,
Richelme H and Milano G: Link between dihydropyrimidine
dehydrogenase activity in peripheral blood mononuclear cells and
liver. Clin Cancer Res. 2:507–510. 1996.PubMed/NCBI
|
|
13
|
Diasio RB: Dihydropyrimidine dehydrogenase
(DPD) deficiency: A 5-fluorouracil-associated pharmacogenomic
syndrome. Horiz Cancer Ther. 4:9–21. 2003.
|
|
14
|
Johnson MR, Wang K and Diasio RB: Profound
dihydropyrimidine dehydrogenase deficiency resulting from a novel
compound heterozygote genotype. Clin Cancer Res. 8:768–774.
2002.PubMed/NCBI
|
|
15
|
Dolegowska B, Ostapowicz A, Stanczyk-Dunaj
M and Blogowski W: Spectrophotometric methods as a novel screening
approach for analysis of dihydropyrimidine dehydrogenase activity
before treatment with 5-fluorouracil chemotherapy. J Physiol
Pharmacol. 63:411–421. 2012.PubMed/NCBI
|
|
16
|
Zhang X, Sun B and Lu Z: Evaluation of
clinical value of single nucleotide polymorphisms of
dihydropyrimidine dehydrogenase gene to predict 5-fluorouracil
toxicity in 60 colorectal cancer patients in China. Int J Med Sci.
10:894–902. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wells GA, Shea B, O'Connell D, et al: The
Newcastle-Ottawa Scale (NOS) for assessing the quality of
nonrandomised studies in meta-analyses. 3rd Symposium on Systematic
Reviews: Beyond the Basics (Oxford, UK). 2000.http://www.ohri.ca/programs/clinical_epidemiology/oxford.htmAccessed.
August 12–2014
|
|
18
|
Cho HJ, Park YS, Kang WK, Kim JW and Lee
SY: Thymidylate synthase (TYMS) and dihydropyrimidine dehydrogenase
(DPYD) polymorphisms in the Korean population for prediction of
5-fluorouracil-associated toxicity. Ther Drug Monit. 29:190–196.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Yamaguchi K, Arai Y, Kanda Y and Akagi K:
Germline mutation of dihydropyrimidine dehydrogenese gene among a
Japanese population in relation to toxicity to 5-Fluorouracil. Jpn
J Cancer Res. 92:337–342. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Sirachainan E, Reungwetwattana T,
Wisetpanit Y, et al: Pharmacogenetic study of 5-FU-related severe
toxicity in Thai cancer patients: A novel SNP detection. J
Pharmacogenomics Pharmacoproteomics. 3:1–4. 2012. View Article : Google Scholar
|
|
21
|
Zhang XP, Bai ZB, Chen BA, Feng JF, Yan F,
Jiang Z, Zhong YJ, Wu JZ, Chen L, Lu ZH, et al: Polymorphisms of
dihydropyrimidine dehydrogenase gene and clinical outcomes of
gastric cancer patients treated with fluorouracil-based adjuvant
chemotherapy in Chinese population. Chin Med J (Engl). 125:741–746.
2012.PubMed/NCBI
|
|
22
|
Rosmarin D, Palles C, Church D, Domingo E,
Jones A, Johnstone E, Wang H, Love S, Julier P, Scudder C, et al:
Genetic markers of toxicity from capecitabine and other
fluorouracil-based regimens: Investigation in the QUASAR2 study,
systematic review, and meta-analysis. J Clin Oncol. 32:1031–1039.
2014. View Article : Google Scholar : PubMed/NCBI
|
